DOCSLIB.ORG

Exploring Alcohol Withdrawal Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exploring Alcohol Withdrawal Syndrome Exploring Alcohol Withdrawal Syndrome DEBORAH A. FINN, PH.D., AND JOHN C. CRABBE, PH.D. Alcohol withdrawal syndrome is characterized by hyperactivity of the nervous system. This hyperactivity represents the brain’s attempt to function normally despite the inhibitory effect of chronic alcohol consumption. The syndrome manifests when alcohol consumption ceases. Experimental, clinical, and genetic research have linked the development of withdrawal to alterations in the sensitivity of neuronal communication systems. Early treatment of the syndrome is advised, because the symptom severity may increase with each subsequent episode. KEY WORDS: AOD withdrawal syndrome; chronic AODE (alcohol and other drug effects); symptom; biological inhibition; neurotransmission; neurochemistry; neurotransmitters; neurotransmitter receptors; animal model; animal strains; membrane channel; genetic mapping; biochemical mechanism; literature review lcohol withdrawal syndrome teins, which bind to neurotransmitters, animal models to study the mecha- consists of unpleasant physical and ion channels through which ions1 nisms and genetics of withdrawal; and Aand mental symptoms follow- (e.g., sodium or calcium) enter the the involvement of neurotransmitters, ing the cessation of alcohol consump- cell. Following repeated administra- receptors, and ion channels in the tion. These symptoms may range from tion of alcohol, the brain attempts to syndrome. For a discussion on the role mild tremor to hallucinations and restore normal functioning through convulsions. Repeated withdrawal adaptations (i.e., tolerance) that re- DEBORAH A. FINN, PH.D., is an episodes may contribute to the devel- duce alcohol’s initial perturbing ef- assistant professor in the Department opment of alcohol dependence and to fects (figure 1). Long-term exposure of Behavioral Neuroscience, Oregon the negative health consequences of to alcohol can lead to physical depen- Health Sciences University, and a drinking. An increased understanding dence, in which neuronal adaptations research pharmacologist at the Dept. of Veterans Affairs Medical Center, of the genetic and biochemical corre- to alcohol become sufficiently pro- Portland, Oregon. lates of the syndrome may lead to nounced that the brain requires the improved treatments for withdrawal continued presence of alcohol to func- JOHN C. CRABBE, PH.D., is a professor as well as for other aspects of alcohol tion normally. When a person termi- in the Department of Behavioral dependence. nates a prolonged drinking session, Neuroscience, Oregon Health The symptoms of withdrawal rep- the adaptations that developed to Sciences University, director of the resent a phase in the alcohol-induced offset alcohol’s initial inhibitory ac- Portland Alcohol Research Center, cycle of neuronal inhibition and exci- tions are unopposed, resulting in a and a research career scientist at the tation. Research has demonstrated that rebound hyperexcitability, or with- Dept. of Veterans Affairs Medical short-term (i.e., acute) administration drawal syndrome. Center, Portland, Oregon. of alcohol can alter the release of This article describes the symp- toms of alcohol withdrawal; the use of Support for this work was provided by chemical messengers (i.e., neurotrans- grants from the National Institute on mitters) from neurons and can disrupt 1For a definition of this and other technical Alcohol Abuse and Alcoholism the function of proteins in neuronal terms used in this article, see central glossary, (AA10760 and AA08621) and the membranes, including receptor pro- pp. 177–179. Department of Veterans Affairs. VOL. 21, NO. 2, 1997 149 Severe alcohol withdrawal is fre- quently complicated in its later stages Drug-free by the presence of delirium tremens + (DT). Patients with DT are agitated, confused, and disoriented, with delu- sions and vivid hallucinations. DT may Acute Chronic Withdrawal persist until 96 hours after cessation of drinking (Victor and Adams 1953). 0 THE KINDLING MODEL OF ALCOHOL WITHDRAWAL Tolerance Last Sedation SEVERITY dose Central Nervous System Activity Several factors are associated with Time increased withdrawal severity, includ- ing increased alcohol consumption, a greater number of prior withdrawal episodes, the occurrence of medical Figure 1 Alcohol’s effect during exposure and withdrawal. The zero line represents problems, and the use of other drugs a hypothetical measure of overall brain excitability. For most physiological in addition to alcohol (Schuckit et al. or behavioral measures, acute alcohol administration produces short-term stimulation (i.e., points above the zero line), followed by depression or 1995). According to one hypothesis sedation (i.e., points below the zero line). Continued alcohol adminis- (Ballenger and Post 1978), repeated tration causes neuronal adaptations that reduce alcohol’s initial perturbing withdrawal episodes increase the effects and result in tolerance. Physical dependence indicates that alcohol severity of subsequent withdrawal is needed to balance the neuronal adaptations and maintain normal brain syndromes as a result of “kindling.” function. Removal of alcohol from the body induces a rebound stimulatory In kindling, a convulsion-promoting effect, resulting in hyperexcitability of the nervous system (i.e., withdrawal drug or electric shock administered syndrome). repeatedly at doses below the effec- SOURCE: Adapted from Metten and Crabbe 1996. tive level for a single administration eventually elicits a convulsion after a single administration. Thus, the neu- rochemical changes that occur during of withdrawal in the development of may occur within the first 2 days of alcohol withdrawal (i.e., reduced addiction, see the article by Roberts abstinence in 5 to 10 percent of pa- function of inhibitory neurotransmis- and Koob, pp. 101–106. tients (Victor and Adams 1953; sion and increased activity of excitatory Schuckit et al. 1995; Yost 1996). neurotransmission) not only contribute SYMPTOMS OF ALCOHOL According to clinical studies, ap- to the withdrawal syndrome, but also WITHDRAWAL proximately 10 percent of alcoholics may cause long-term changes in brain may develop an additional set of with- excitability by a kindlinglike process Alcohol withdrawal is characterized by drawal symptoms. These symptoms (Glue and Nutt 1990). Consistent with symptoms of hyperactivity of the auto- represent a combination of marked the kindling hypothesis, the severity nomic nervous system, a division of autonomic nervous system hyperactiv- of withdrawal in mice, measured by the nervous system that helps manage ity, including large increases in blood handling-induced convulsions the body’s response to stress (Schuckit pressure, pulse, breathing rate, and (HIC’s), increases with repeated expo- et al. 1995; Yost 1996). Alcoholics heart rate, as well as elevated body sure to alcohol vapor and subsequent often continue to consume alcohol to temperature. Drenching sweats can withdrawal episodes compared with relieve or avoid withdrawal symptoms. cause severe dehydration, and tremor mice that received an equivalent dose The initial symptoms usually are can become sufficiently pronounced of alcohol vapor in a single adminis- relatively mild and include anxiety, to prevent the patient from performing tration (Becker and Hale 1993). insomnia, and tremors. These symp- such simple activities as manipulating Therefore, both animal and human toms may begin within 3 to 6 hours an eating utensil. Typically, these studies indicate a greater likelihood of following cessation of drinking and more severe symptoms peak in inten- severe withdrawal symptoms in pa- often before the blood alcohol concen- sity between the third and fourth days tients who have experienced a greater tration (BAC) has returned to zero. of abstinence and generally improve number of past withdrawal episodes. The symptoms usually abate within by the fifth day (Schuckit et al. 1995) These data suggest that early treat- 1 to 3 days. Severe convulsions also (figure 2). ment for alcohol withdrawal convul- 150 ALCOHOL HEALTH & RESEARCH WORLD Alcohol WithdrawalRunning Syndrome Heads sions may minimize increased with- and provide an overview of the main drawal severity in subsequent findings with each animal model. 70 episodes by preventing this kindling- 60 like process. Research is needed to Inbred Strains confirm this possibility. 50 An inbred strain is derived from 20 40 generations of brother-sister matings, 30 ANIMAL MODELS OF ALCOHOL resulting in a population of animals 20 WITHDRAWAL that is essentially genetically identical. 10 Thus, trait variation within an inbred Percentage of patients 0 Researchers have used various meth- strain can be attributed to environ- 123456714 ods to induce physical dependence in mental causes, whereas variation Days After Cessation of Drinking animals in order to define and quanti- between inbred strains can be attribut- fy the withdrawal syndrome. The ed to genetic causes. Studies docu- Convulsions (68 patients) most common paradigms utilize a Transient hallucinations menting differences in alcohol (50 patients) nutritionally balanced liquid diet con- withdrawal severity among inbred Tremors (50 patients) taining alcohol, inhalation of alcohol strains show clear evidence of genetic Motor and autonomic vapor, or multiple daily doses of alco- overactivity, confusion, and influence (Kakihana 1979; Crabbe et disordered sense perception hol administered either by injection or al. 1983). (44 patients) by a tube inserted into the esophagus One
Load more

Recommended publications
  • Perceptions of Powdered Alcohol and Intentions to Use: an Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults
    Beverages 2015, 1, 329-340; doi:10.3390/beverages1040329 OPEN ACCESS beverages ISSN 2306-5710 www.mdpi.com/journal/beverages Article Perceptions of Powdered Alcohol and Intentions to Use: An Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults John Stogner 1,*, Julie M. Baldwin 2, Timothy Brown 3 and Taylor Chick 1 1 Department of Criminal Justice and Criminology, University of North Carolina at Charlotte, 9201 University Boulevard., Charlotte, NC 28223, USA; E-Mail: [email protected] 2 Department of Criminology and Criminal Justice, Missouri State University, 901 S. National Strong Hall Room. 226, Springfield, MO 65897, USA; E-Mail: [email protected] 3 Department of Criminal Justice, University of Arkansas at Little Rock, Ross Hall 5th Floor, Little Rock, AR 72204, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-704-687-8446; Fax: +1-704-687-5285. Academic Editor: Edgar Chambers IV Received: 14 October 2015 / Accepted: 17 November 2015 / Published: 1 December 2015 Abstract: While there seems to be growing media intrigue over atypical forms of alcohol use, the utilization of the majority of novel consumption methods (e.g., eyeballing, slimming, alcohol without liquid (AWOL)) seems minimal. In 2014, however, several outlets suggested that powdered alcohol would soon surface as a threat to public safety. The impetus of these fears was the Alcohol and Tobacco Tax and Trade Bureau’s approval for Lipsmark LLC to package a powdered alcohol product named “Palcohol”. Palcohol has yet to reach store shelves, but public outcry has been intense.
    [Show full text]
  • Redalyc.Timing of Progesterone and Allopregnanolone Effects in a Serial
    Salud Mental ISSN: 0185-3325 [email protected] Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz México Contreras, Carlos M.; Rodríguez-Landa, Juan Francisco; Bernal-Morales, Blandina; Gutiérrez-García, Ana G.; Saavedra, Margarita Timing of progesterone and allopregnanolone effects in a serial forced swim test Salud Mental, vol. 34, núm. 4, julio-agosto, 2011, pp. 309-314 Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Distrito Federal, México Available in: http://www.redalyc.org/articulo.oa?id=58221317003 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Salud Mental 2011;34:309-314Timing of progesterone and allopregnanolone effects in a serial forced swim test Timing of progesterone and allopregnanolone effects in a serial forced swim test Carlos M. Contreras,1,2 Juan Francisco Rodríguez-Landa,1 Blandina Bernal-Morales,1 Ana G. Gutiérrez-García,1,3 Margarita Saavedra1,4 Artículo original SUMMARY Total time in immobility was the highest and remained at similar levels only in the control group throughout the seven sessions of the The forced swim test (FST) is commonly employed to test the potency serial-FST. In the allopregnanolone group a reduction in immobility of drugs to reduce immobility as an indicator of anti-despair. Certainly, was observed beginning 0.5 h after injection and lasted approximately antidepressant drugs reduce the total time of immobility and enlarge 1.5 h. Similarly, progesterone reduced immobility beginning 1.0 h the latency to the first immobility period.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Methanol Interim AEGL Document
    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
    [Show full text]
  • An Advanced Drug Delivery System Targeting Brain Through BBB
    pharmaceutics Review Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB Mantosh Kumar Satapathy 1 , Ting-Lin Yen 1,2,† , Jing-Shiun Jan 1,†, Ruei-Dun Tang 1,3, Jia-Yi Wang 3,4,5 , Rajeev Taliyan 6 and Chih-Hao Yang 1,5,* 1 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] (M.K.S.); [email protected] (T.-L.Y.); [email protected] (J.-S.J.); [email protected] (R.-D.T.) 2 Department of Medical Research, Cathay General Hospital, Taipei 22174, Taiwan 3 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] 4 Department of Neurosurgery, Taipei Medical University Hospital, Taipei 110, Taiwan 5 Neuroscience Research Center, Taipei Medical University, Taipei 110, Taiwan 6 Department of Pharmacy, Neuropsychopharmacology Division, Birla Institute of Technology and Science, Pilani 333031, India; [email protected] * Correspondence: [email protected]; Tel.: +886-2-2736-1661 (ext. 3197) † These authors contributed equally to this work. Abstract: The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among Citation: Satapathy, M.K.; Yen, T.-L.; some of the limitations associated with current neurotherapeutics.
    [Show full text]
  • Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R
    Article Cite This: Cryst. Growth Des. 2019, 19, 4101−4108 pubs.acs.org/crystal In the Context of Polymorphism: Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R. Vazqueź Marrero, , Carmen Piñero Berríos, , Luz De Dios Rodríguez, , ‡ ∥ ‡ § Torsten Stelzer,*, , and Vilmalí Lopez-Mej́ ías*, , † Department of Biology, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ‡ Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States § Department of Chemistry, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ∥ Department of Pharmaceutical Sciences, University of Puerto RicoMedical Sciences Campus, San Juan, Puerto Rico 00936, United States *S Supporting Information ABSTRACT: Solubility measurements for polymorphic com- pounds are often accompanied by solvent-mediated phase transformations. In this study, solubility measurements from undersaturated solutions are employed to investigate the solubility of the two most stable polymorphs of flufenamic acid (FFA forms I and III), tolfenamic acid (TA forms I and II), and the only known form of niflumic acid (NA). The solubility was measured from 278.15 to 333.15 K in four alcohols of a homologous series (methanol, ethanol, 1- propanol, n-butanol) using the polythermal method. It was established that the solubility of these compounds increases with increasing temperature. The solubility curves of FFA forms I and III intersect at ∼315.15 K (42 °C) in all four solvents, which represents the transition temperature of the enantiotropic pair. In the case of TA, the solubility of form II could not be reliably obtained in any of the solvents because of the fast solvent- mediated phase transformation.
    [Show full text]
  • Is Cannabis Addictive?
    Is cannabis addictive? CANNABIS EVIDENCE BRIEF BRIEFS AVAILABLE IN THIS SERIES: ` Is cannabis safe to use? Facts for youth aged 13–17 years. ` Is cannabis safe to use? Facts for young adults aged 18–25 years. ` Does cannabis use increase the risk of developing psychosis or schizophrenia? ` Is cannabis safe during preconception, pregnancy and breastfeeding? ` Is cannabis addictive? PURPOSE: This document provides key messages and information about addiction to cannabis in adults as well as youth between 16 and 18 years old. It is intended to provide source material for public education and awareness activities undertaken by medical and public health professionals, parents, educators and other adult influencers. Information and key messages can be re-purposed as appropriate into materials, including videos, brochures, etc. © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018 Publication date: August 2018 This document may be reproduced in whole or in part for non-commercial purposes, without charge or further permission, provided that it is reproduced for public education purposes and that due diligence is exercised to ensure accuracy of the materials reproduced. Cat.: H14-264/3-2018E-PDF ISBN: 978-0-660-27409-6 Pub.: 180232 Key messages ` Cannabis is addictive, though not everyone who uses it will develop an addiction.1, 2 ` If you use cannabis regularly (daily or almost daily) and over a long time (several months or years), you may find that you want to use it all the time (craving) and become unable to stop on your own.3, 4 ` Stopping cannabis use after prolonged use can produce cannabis withdrawal symptoms.5 ` Know that there are ways to change this and people who can help you.
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • Formulation and Evaluation of Nitrendipine Buccal Films
    www.ijpsonline.com SShorthort CCommunicationsommunications Formulation and Evaluation of Nitrendipine Buccal Films M. NAPPINNAI*, R. CHANDANBALA AND R. BALAIJIRAJAN Department of Pharmaceutics, C. L. Baid Mehta College of Pharmacy, Jyothi Nagar, Thoraipakkam, Old Mahabalipuram Road, Chennai-600 096, India Nappinnai, et al.: Nitrendipine buccal fi lms A mucoadhesive drug delivery system for systemic delivery of nitrendipine, a calcium channel blocker through buccal route was formulated. Mucoadhesive polymers like hydroxypropylmethylcellulose K-100, hydroxypropylcellulose, sodium carboxymethylcellulose, sodium alginate, polyvinyl alcohol, polyvinyl pyrrolidone K-30 and carbopol- 934P were used for fi lm fabrication. The fi lms were evaluated for their weight, thickness, percentage moisture absorbed and lost, surface pH, folding endurance, drug content uniformity, In vitro residence time, In vitro release and ex vivo permeation. Based on the evaluation of these results, it was concluded that buccal fi lms made of hydroxylpropylcellulose and sodium carboxymethylcellulose (5±2% w/v; F-4), which showed moderate drug release (50% w/w at the end of 2 h) and satisfactory fi lm characteristics could be selected as the best among the formulations studied. Key words: Buccal fi lms, carboxymethylcellulose, hydroxylpropylcellulose, nitrendipine Mucoadhesive drug delivery systems may be bioadhesive polymers was executed. formulated to adhere to the mucosa of eyes, nose, oral (buccal), intestine, rectum and vagina1. Among these Nitrendipine (NTD) was obtained as a gift systems, the buccal mucosa offers many advantages sample from M/s. Camlin Ltd., Mumbai. like relatively large surface area of absorption, easy Hydroxypropylmethylcellulose K-100 (HPMC accessibility, simple delivery devices, avoiding hepatic K-100) and hydroxypropylcellulose (HPC) were first pass metabolism and feasibility of controlled purchased from Lab Chemicals, Chennai.
    [Show full text]
  • Can Tobacco Dependence Provide Insights Into Other Drug Addictions? Joseph R
    DiFranza BMC Psychiatry (2016) 16:365 DOI 10.1186/s12888-016-1074-4 DEBATE Open Access Can tobacco dependence provide insights into other drug addictions? Joseph R. DiFranza Abstract Within the field of addiction research, individuals tend to operate within silos of knowledge focused on specific drug classes. The discovery that tobacco dependence develops in a progression of stages and that the latency to the onset of withdrawal symptoms after the last use of tobacco changes over time have provided insights into how tobacco dependence develops that might be applied to the study of other drugs. As physical dependence on tobacco develops, it progresses through previously unrecognized clinical stages of wanting, craving and needing. The latency to withdrawal is a measure of the asymptomatic phase of withdrawal, extending from the last use of tobacco to the emergence of withdrawal symptoms. Symptomatic withdrawal is characterized by a wanting phase, a craving phase, and a needing phase. The intensity of the desire to smoke that is triggered by withdrawal correlates with brain activity in addiction circuits. With repeated tobacco use, the latency to withdrawal shrinks from as long as several weeks to as short as several minutes. The shortening of the asymptomatic phase of withdrawal drives an escalation of smoking, first in terms of the number of smoking days/ month until daily smoking commences, then in terms of cigarettes smoked/day. The discoveries of the stages of physical dependence and the latency to withdrawal raises the question, does physical dependence develop in stages with other drugs? Is the latency to withdrawal for other substances measured in weeks at the onset of dependence? Does it shorten over time? The research methods that uncovered how tobacco dependence emerges might be fruitfully applied to the investigation of other addictions.
    [Show full text]
  • Patient-Focused Drug Development Meeting on Opioid Use Disorder
    Patient-Focused Drug Development Meeting on Opioid Use Disorder April 17, 2018 FDA will be streaming a live audio recording of the meeting with the presentation slides, which is open to the public at: https://collaboration.fda.gov/pfdd041718/. The audio recording and presentation slides, along with a meeting transcript and summary report, will also be made publicly available after the meeting. Because of the sensitive nature of the meeting topic, and the importance of gathering candid, meaningful input from individuals who have come forward to speak about living with opioid use disorder, no other audio recording, video recording, and/or photography will be allowed at this Patient-Focused Drug Development meeting. FDA is asking for your cooperation and strongly requests that you respect the privacy of all attendees. #PFDD Wi-Fi Network: FDA-Public Password: publicaccess Welcome Sara Eggers, PhD Office of Strategic Programs Center for Drug Evaluation and Research April 17, 2018 U.S. Food and Drug Administration Agenda • Opening Remarks • Setting the context – Overview of Opioid Use Disorder – Road from PFDD Meetings to Clinical Trial Endpoints – Overview of Discussion Format • Discussion Topic 1 • Lunch • Discussion Topic 2 (with a short break) • Open Public Comment • Closing Remarks 3 3 No Recording or Photography • FDA is streaming a live audio recording of the meeting with the presentation slides, which is open to the public – Access the live stream: https://collaboration.fda.gov/pfdd041718/. – The audio recording and presentation slides, along with a meeting transcript and summary report, will also be made publicly available after the meeting. • Because of the sensitive nature of the meeting topic, and the importance of gathering candid, meaningful input from individuals who have come forward to speak about living with opioid use disorder, no other audio recording, video recording, and/or photography will be allowed at this Patient-Focused Drug Development meeting.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]